

L Number	Hits	Search Text	DB	Time stamp
1	7	"2078564"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/07/26 10:53
5	9	"1145623"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/07/26 11:29
-	219	"N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]-beta-Alanine" "N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-(R)-beta-Alanine" "d-Pantothenic acid"  "(+)-Pantothenic acid" "(D)-(+)-Pantothenic acid" "Chick antidermatitis factor" "D(+)-N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-.beta.-alanine" "D-Pantothenic acid" "Pantothenic acid" "Vitamin B3" "Vitamin B5"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/07/26 10:53
-	36	"N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]-beta-Alanine" "N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-(R)-beta-Alanine" "d-Pantothenic acid"  "(+)-Pantothenic acid" "(D)-(+)-Pantothenic acid" "Chick antidermatitis factor" "D(+)-N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-.beta.-alanine" "D-Pantothenic acid" "Pantothenic acid" "Vitamin B3" "Vitamin B5"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/07/25 14:21
-	0	) and inject\$5  "Pantothen\$4"	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/07/25 14:23
-	8214	Pantothen\$4	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/07/25 14:23
-	113	Pantothen\$4 same inflammat\$4	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/07/25 14:23
-	134	Pantothen\$4 same (inflammat\$4 pain\$4)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/07/25 14:24
-	47	Pantothen\$4 same (inflammat\$4 pain\$4) and inject\$5	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/07/26 11:29

L22 ANSWER 46 OF 54 USPATFULL on STN  
ACCESSION NUMBER: 94:33239 USPATFULL  
TITLE: Methods of treatment of clinical conditions using  
pantothenic acid  
INVENTOR(S): Leung, Lit-Hung, Room 502, Dragon Seed Building, 39  
Queen's Road Central, Hong Kong, Hong Kong

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5304574		19940419	<--
APPLICATION INFO.:	US 1992-927189		19920807	(7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-713965, filed on 11 Jun 1991, now abandoned			

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1991-2830	19910211
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Cintins, Marianne M.	
ASSISTANT EXAMINER:	Cook, Rebecca	
LEGAL REPRESENTATIVE:	Thompson, Hine and Flory	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	732	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating human beings suffering from chronic bronchial  
asthma, acute rhinitis, disseminated lupus erythematosus, or  
neurodermatitis which comprises administering to said human being a  
therapeutically effective amount of pantothenic acid or a derivative.

L22 ANSWER 51 OF 54 USPATFULL on STN

ACCESSION NUMBER: 86:60714 USPATFULL

TITLE: Utilization of a single vitamin or a combination of various vitamins

INVENTOR(S): Motschan, Georges, Schonbeinstrasse 21, 4056 Basel, Switzerland

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4619829		19861028	<--
	WO 8401899		19840524	<--
APPLICATION INFO.:	US 1984-631555		19840713	(6)
	WO 1983-CH127		19831116	
			19840713	PCT 371 date
			19840713	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1982-6682	19821116
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Robinson, Douglas W.	
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	637	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention refers to a new utilization of a unique vitamin or a combination of various vitamins in the long-term treatment and/or prevention of rheumatic diseases.

During a long-term treatment and/or prevention of rheumatic diseases, a unique vitamin or a combination of various vitamins is administered to a patient.

L7 ANSWER 30 OF 43 CA COPYRIGHT 2003 ACS on STN DUPLICATE 4  
 ACCESSION NUMBER: 120:124882 CA  
 TITLE: Amines and amine-related derivatives of benzoic acid  
 for treating inflammatory diseases  
 INVENTOR(S): Shapiro, Howard K.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9400135	A1	19940106	WO 1993-US6167	19930629
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, SK, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9346553	A1	19940124	AU 1993-46553	19930629
AU 674330	B2	19961219		
EP 604641	A1	19940706	EP 1993-916834	19930629
EP 604641	B1	20020320		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 214608	E	20020415	AT 1993-916834	19930629
PRIORITY APPLN. INFO.:			US 1992-906909	A2 19920630
			WO 1993-US6167	A 19930629

OTHER SOURCE(S): MARPAT 120:124882

AB Amines capable of covalently binding carbonyl substances, in combination with other agents such as antioxidants, free radical scavengers, and vitamins are used for the treatment of chronic inflammatory disorders featuring oxidative free radical reactions, lipid peroxidn., and generation of carbonyl compds. A clin. study showed that an administration of vitamin E 800 IU, methionine 1g, and PABA 1.1g per day to a patient with arthritis decreased **pain** and improved functional status.

L7 ANSWER 21 OF 43 USPATFULL on STN

ACCESSION NUMBER: 1999:132886 USPATFULL

TITLE: L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism

INVENTOR(S): Howard, James R., 277 West "G" St., Brawley, CA, United States 92227

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5973004		19991026
APPLICATION INFO.:	US 1998-3337		19980106 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-826555, filed on 4 Apr 1997, now patented, Pat. No. US 5889055		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	MacMillan, Keith D.		
LEGAL REPRESENTATIVE:	Nixon & Vanderhye P.C.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1118		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A combination can be of L-carnitine and acetyl-L-carnitine, preferably with pantothenic acid or ubiquinone, is administered orally or as a parenteral **injection** in domesticated animals, especially pet animals, and humans for prevention or treatment of syndromes or diseases arising from dysfunctional energy metabolism. Syndromes involving skeletal and cardiac muscle benefited from L-carnitine, and syndromes related to the central nervous system improved with acetyl-L-carnitine, are effectively treated. The cofactors L-carnitine and acetyl-L-carnitine do not substitute metabolically for each other, and the effects of the combination are found to be synergistic.

L7 ANSWER 16 OF 43 USPATFULL on STN  
 ACCESSION NUMBER: 2002:224270 USPATFULL  
 TITLE: Methods of treating chronic inflammatory diseases using  
 carbonyl trapping agents  
 INVENTOR(S): Shapiro, Howard K., 214 Price Ave., Apt. F-32,  
 Narberth, PA, United States 19072

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6444221	B1	20020903
APPLICATION INFO.:	US 1999-416120		19991012 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-473786, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1992-906909, filed on 30 Jun 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kulkosky, Peter F.		
ASSISTANT EXAMINER:	Di Nola-Baron, Liliana		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	2400		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The carbonyl sequestering agents are used in combination with at least one co-agent so as to produce an additional beneficial physiological effect of an anti-inflammatory nature. Such compositions are administered systemically entirely via the oral route. Co-agents of the present invention include anti-oxidants and free radical trapping compounds (e.g., .alpha.-tocopherol), compounds having indirect anti-oxidant activity (e.g., selenium), vitamins (e.g., pyridoxine HCl), compounds which facilitate kidney drug elimination (e.g., glycine), metabolites at risk of depletion (e.g., pantothenic acid), sulfhydryl containing chemicals (e.g., methionine), compounds which facilitate glutathione activity (e.g., N-acetylcysteine), and non-absorbable polyamine co-agents (e.g., chitosan).

L7 ANSWER 39 OF 43 IFICDB COPYRIGHT 2003 IFI on STNDUPLICATE 5

AN 1750199 IFIPAT;IFIUDB;IFICDB  
TITLE: COMPOSITION FOR RELIEVING TOOTHACHE PAIN  
AND OTHER FORMS OF INTENSE PAIN  
INVENTOR(S): Barron, Larry, 7 Hamilton Avenue, Winnipeg, Manitoba,  
CA  
Barron, Susan C, 7 Hamilton Avenue, Winnipeg,  
Manitoba, CA  
PATENT ASSIGNEE(S): Unassigned  
PRIMARY EXAMINER: Moyer, Donald B  
ASSISTANT EXAMINER: Rollins, Jr, John W  
AGENT: Garrett, Kenneth M

	NUMBER	PK	DATE
PATENT INFORMATION:	US 4650668		19870317
	(CITED IN 003 LATER PATENTS)		
APPLICATION INFORMATION:	US 1984-685080		19841221
EXPIRATION DATE:	21 Dec 2004		
FAMILY INFORMATION:	US 4650668		19870317
DOCUMENT TYPE:	UTILITY		
	EXPIRED		
FILE SEGMENT:	CHEMICAL		
	GRANTED		
NUMBER OF CLAIMS:	5		

AB A treatment for temporary relief of **pain** wherein a single dose comprises the following: 4 grams calcium gluconate by **injection**, 1 gram Vitamin C (calcium ascorbate), 100 mg magnesium hydroxide, 50 mg Vitamin B6 (pyridoxine hydrochloride), 1 gram pantothenic acid, effervescent solution.

CLMN 5

L7 ANSWER 40 OF 43 CA COPYRIGHT 2003 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 105:197195 CA  
TITLE: Composition for relieving toothache **pain** and  
other forms of intense **pain**  
INVENTOR(S): Barron, Larry; Barron, Susan  
PATENT ASSIGNEE(S): Can.  
SOURCE: Can., 6 pp.  
CODEN: CAXXA4  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 1208132	A1	19860722	CA 1985-477206	19850322
US 4650668	A	19870317	US 1984-685080	19841221
PRIORITY APPLN. INFO.:			US 1985-685080	19851221
			CA 1985-477206	19850322

AB An improved formulation for relieving temporarily tooth **pain** and other forms of intense **pain** with no side effects consists of a kit comprising 2 parts: the 1st part contains 1-4 g Ca gluconate in an **injectable** form and the 2nd part contains a compn. prepd. from 1-4 g pantothenic acid (optionally as Ca salt), 500 mg-4 g vitamin C (as Ca ascorbate), 50-100 mg vitamin B6 and 100-300 mg Mg(OH)2 in a form suitable for oral administration. The 2nd part further includes NaHCO3 and citric acid in amts. sufficient to render the compn. effervescent in water prior to administration. The formulation allows the Ca to be available all at once. Following the Ca gluconate **injection** the individual patient is given the effervescent part by oral administration thereby enhancing the effectiveness of the Ca in providing relief.

L22 ANSWER 1 OF 54 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
ACCESSION NUMBER: 1982:305378 BIOSIS  
DOCUMENT NUMBER: BA74:77858  
TITLE: ANTI INFLAMMATORY AND COENZYMIC ACTIVITY OF  
PANTOTHENIC-ACID DERIVATIVES IN ADJUVANT ARTHRITIS.  
AUTHOR(S): MOISEENOK A G; ASTRAUSKAS V I; GURINOVICH V A; SHEIBAK V M;  
PRON'KO P S; KHOMICH T I; DENISOVA N K; GUNAR V I;  
KOPELEVICH V M; ET AL  
CORPORATE SOURCE: DEP. METAB. REGUL., ACAD. SCI. B. SSR, GRODNO, USSR.  
SOURCE: KHM-FARM ZH, (1981) 15 (6), 76-81.  
CODEN: KHFZAN. ISSN: 0023-1134.  
FILE SEGMENT: BA; OLD  
LANGUAGE: Russian

AB The antiinflammatory and coenzymic activity of calcium  
**pantothenate**, 4'-phosphopantothenic acid, sulfopantetheine,  
pantethine, homopantothenate and pantoyleaminocaproate was studied in  
experiments on white rats with adjuvant arthritis. Vitamin derivatives,  
especially **pantothenate**, decreased swelling intensity of  
joints in experimental animals only when a course introduction at  
a dose of 30 mg/kg preceded the induction of arthritis. This was probably  
related to the effect of the **inflammatory** process on the  
induction phase. During the developmental stage of polyarthritis, when the  
antiinflammatory effect of **pantothenic** acid derivatives was not  
manifested, an increase was observed in the total **pantothenate**  
content and the content of CoA precursors in hepatocytes, and in the  
myocardium in animals injected with the preparations. The level  
of total CoA increased only with calcium **pantothenate**  
introduction. Application of calcium **pantothenate** derivatives  
caused a normalization in the activity of enzymes of nonspecific CoA  
hydrolysis.